Applies to the following strength(s): 45 mg30 mg15 mg
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Diabetes Type 2
-Patients without congestive heart failure: 15 mg or 30 mg orally once a day
-Patients with congestive heart failure (New York Heart Association [NYHA] Class I or II): 15 mg orally once a day
Maintenance dose: 15 mg to 45 mg orally once a day based on glycemic response as determined by HbA1c
Maximum dose: 45 mg orally once a day
-This drug can be taken without regard to meals.
Use: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
No adjustment recommended; however, caution is recommended in patients with liver disease.
Concomitant use with an insulin secretagogue (e.g., sulfonylurea): If hypoglycemia occurs, the dose of the insulin secretagogue should be reduced.
Concomitant use with insulin: If hypoglycemia occurs, the dose of insulin should be reduced by 10% to 25%. Additional adjustments to the insulin dose should be individualized based on glycemic response.
Concomitant use with gemfibrozil or other strong CYP450 2C8 inhibitors: the maximum recommended dose is 15 mg a day
-Thiazolidinediones cause or exacerbate congestive heart failure in some patients.
-After initiation of therapy, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone must be considered.
-Pioglitazone is not recommended in patients with symptomatic heart failure.
-Initiation of therapy in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Protect from light, moisture and humidity
-After initiation of therapy or with dose increase, monitor patients for adverse reactions related to fluid retention (weight gain, edema, and signs and symptoms of congestive heart failure).
-Patients who have developed liver test abnormalities prior to initiation of therapy or who are found to have abnormal liver tests while using this drug should be managed according to current standards of care.
More about pioglitazone
- Other brands: Actos